-
29-05-2015
GGGNNNIIIPPPSSSTTT BBBUUULLLLLLEEETTTIIINNN 22200011155529th
May, 2015 Volume No.: 45 Issue No.: 04
Vision
TO REACH THE PINNACLE OF GLORY AS A CENTRE OF EXCELLENCE IN THE
FIELD OF PHARMACEUTICAL AND BIOLOGICAL SCIENCES BY KNOWLEDGE
BASED LEARNING AND PRACTICE
Contents Message from PRINCIPAL Editorial board Historical
article News Update Knowledge based Article Disease Related
Breaking
News Upcoming Events Drugs Update Campus News Students Section
Editors Note Archive
GNIPST Photo Gallery For your comments/contribution OR For
Back-Issues, mailto:[email protected]
GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY W
e bs i t e : ht t p: / / gni ps t. a c. i n
-
29-05-2015
MESSAGE FROM PRINCIPAL
"It can happen. It does happen. But it can't happen if you
quit." Lauren Dane.
We are what we repeatedly do. Excellence then is not an act, but
a habit. Aristotle
It gives me immense pleasure to pen a few words for our
e-bulletin. At the onset I would like to thank the last years
editors and congratulate the newly selected editors for the current
year.
Our first consideration is always in the best interest of the
students. Our goal is to promote academic excellence and continuous
improvement.
I believe that excellence in education is aided by creating a
learning environment in which all learners are supported in
maximizing their potential and talents. Education needs to focus on
personalized learning and instruction, while promoting an education
system that is impartial, universally accessible, and meeting the
needs of all students.
It is of paramount importance that our learners have sufficient
motivation and encouragement in order to achieve their aims. We are
all very proud of you, our students, and your accomplishments and
look forward to watching as you put your mark on the profession in
the years ahead.
The call of the time is to progress, not merely to move ahead.
Our progressive Management is looking forward and wants our
Institute to flourish as a Post Graduate Institute of Excellence.
Steps are taken in this direction and fruits of these efforts will
be received by our students in the near future. Our Teachers are
committed and dedicated for the development of the institution by
imparting their knowledge and play the role of facilitator as well
as role model to our students.
The Pharmacy profession is thriving with a multitude of
possibilities, opportunities and positive challenges. At Guru Nanak
Institute of Pharmaceutical Science and Technology, our focus is on
holistic needs of our students.
I am confident that the students of GNIPST will recognize all
the possibilities, take full advantage of the opportunities and
meet the challenges with purpose and determination.
Excellence in Education is not a final destination, it is a
continuous walk. I welcome you to join us on this path.
My best wishes to all.
Dr. A. Sengupta
Click here to go at the top
1
-
29-05-2015
EDITORIAL BOARD
CHIEF EDITOR DR. ABHIJIT SENGUPTA EDITOR MS. JEENATARA BEGUM
ASSOCIATE EDITOR MR. DIPANJAN MANDAL
HISTORICAL ARTICLE Pharmaceutical Manufacturing Comes of Age:
Pharmaceutical manufacturing as an industry apart from retail
Pharmacy had its beginnings about 1600; really got under way in the
middle 1700's. It developed first in Germany, then in England and
in France. In America, it was the child of wars - born in the
Revolution; grew rapidly during and following the Civil War; became
independent of Europe during World War I; came of age during and
following World War II. Utilizing latest technical advances from
every branch of science, manufacturing Pharmacy economically
develops and produces the latest and greatest in drugs in immense
quantities, so that everywhere physicians may prescribe them and
pharmacists dispense them for the benefit of all mankind.
NEWS UPDATE Smokers and those exposed to passive smoke
require more anesthetic and painkiller during operations: (29th
May,2015) New research shows that both smokers and those exposed to
passive smoke require more anesthetic and painkillers to reach the
same level of anesthesia as non-smokers.
Click here to go at the top
2
-
29-05-2015
Before an operation, low blood pressure rather than high is a
risk factor for death: (29th May,2015) New research suggests that,
before an operation, low blood pressure rather than high blood
pressure is an independent risk factor for death.
Hypothermia occurs during surgery in around half of patients:
(29th May,2015) A study shows that hypothermia occurs in around
half of patients undergoing surgery, despite national guidelines
for its prevention.
Blood pressure medications can lead to increased risk of stroke:
(29th May,2015) The importance of preventing hypertension is
reinforced by a study showing anti-hypertension medicines can
increase stroke risk by 248 percent, according to new research.
Phase 2 trial identifies genetic dysfunction that makes many
types of cancer vulnerable to an immunotherapy: (29th May,2015) A
team of researchers has identified a genetic malfunction that
predicts the effectiveness of response to a groundbreaking
immunotherapy. The results of their Phase 2 clinical trial reveal
that, regardless of its tissue of origin, tumors whose cells are
deficient in repairing mismatched DNA sequences--and so preventing
mutations--are far more susceptible to the checkpoint inhibitor
pembrolizumab than those that retain this ability.
Click here to go at the top
3
-
29-05-2015
Altered pain processing in patients with cognitive impairment:
(29th May,2015) People with dementia and other forms of cognitive
impairment (CI) have altered responses to pain, with many
conditions associated with increased pain sensitivity, concludes a
new research review.
Less-invasive method for kidney diagnostics: (29th May,2015)
Researchers have identified a new, less-invasive method to provide
diagnostic information on kidney disease and its severity.
Alzheimer's culprit causes memory loss even before brain
degeneration: (29th May,2015) A brain protein believed to be a key
component in the progress of dementia can cause memory loss in
healthy brains even before physical signs of degeneration appear,
according to new research.
Rewriting the book on chemo-resistant cancers with a DNA
library: (29th May,2015) Researcher are finding out why ovarian
cancer is resistant to certain types of chemo and hope to
eventually identify a different drug target.
Biomarker analysis reveals several potential treatment targets
in subtype of anal cancer: (29th May,2015) A multiplatform
biomarker analysis of squamous cell anal carcinoma samples has
revealed several actionable targets. For detail mail to editor
Click here to go at the top
4
-
29-05-2015
KNOWLEDGE BASED ARTICLE Lassa Fever
Description: An extremely virulent, often fatal, Old-World,
viral hemorrhagic illness. Lassa fever, an arenavirus, is an
enveloped, single-stranded, bisegmented RNA virus. As with other
arenaviruses, Lassa virus does not have a conventional
negative-strand coding arrangement. Lassa fever occurs more often
in the dry season, rather than in the rainy season. It is the most
commonly "exported" hemorrhagic fever; its victims carry the
disease from Africa to the United States, to the United Kingdom, tp
the Netherlands, Israel, and Japan. Lassa fever is named after the
town (in the Yedseram River valley) in which the first cases were
isolated in 1969, during a nosocomial outbreak at a local hospital.
(A clinical description of Lassa fever was published in Sierra
Leone over a decade earlier, but received little or no attention.)
Location: Parts of West Africa, including Guinea, Sierra Leone,
Nigeria, and Liberia. However, sporadic Lassa infections may have
also occurred in Senegal and Mali. One host genus has been
identified as spreading at least one Lassalike virus in central
Africa. Vector: The rat species Mastomys, in particular, M.
natalensis. This is a consistent host reservoir for the Lassa virus
because of congenital neonatal infection, which results in rats
with long-lasting and/or lifelong infection. Because of the
mechanism of infection, there is no break in the natural chain from
virus to host species. The rats themselves might show no symptoms
of the disease, but they shed the virus freely in urine and
droppings, and secrete the virus in their saliva. Because certain
varieties of Mastomys often live in human homes, the virus is
easily transmitted to humans. Transmission occurs via direct
contact with rat urine, feces, and saliva; via contact with
excretion- or secretion-infected materials; or via ingestion of
excretion-contaminated food. Victims can also become infected
Click here to go at the top
5
-
29-05-2015
via skin breaks, and via mucous membranes from aerosol
transmission from dust-borne particles. In some areas, the rodents
are used as a food source, thus providing additional exposure to
the infected rat blood, as well as allowing ingestion of
potentially contaminated meat. Laboratory workers become infected
usually from contact with rodent saliva. Unlike other arenaviruses,
Lassa virus can be fairly easily transmitted from human to human.
Humans can contract the disease from other humans via aerosol
transmission (coughing), or from direct contact with infected human
blood, urine, or semen. Lassa virus has been isolated from semen 6
weeks after acute illness; the virus can be transmitted to sexual
partners by convalescent men. Mechanism: The virus enters the human
body through the bloodstream, lymph vessels, respiratory tract,
and/or digestive tract. It then multiplies in cells of the
reticuloendothelial system. Virus replication in the
reticuloendothelial cells causes capillary lesions. These capillary
lesions lead to erythrocyte and platelet loss, with mild to
moderate thrombocytopenia and a tendency toward bleeding. Capillary
lesions also cause increased vascular permeability and hemorrhage
in various organs, such as the stomach, small intestine, kidneys,
lungs, and brain. Incubation Period: Usually about 10 days. Can
range from 1-24 days. Most patients display symptoms for 4 to 5
days before seeking hospital treatment. Symptoms: Gradual onset of
fever and malaise. Increased fever (which can last 2-3 weeks) and
myalgia, with severe prostration, accompanied by involvement of
specific organs and serosa. Patients frequently present with pain
behind the sternum and with coughing. Additional common symptoms
include: abdominal pain, nausea and vomiting, diarrhea, or
constipation; also: conjunctivitis, pharyngitis (inflammation of
mucous membranes and the
Click here to go at the top
6
-
29-05-2015
underlying parts of the pharynx), increased vascular
permeability (such as pleural effusions), and proteinuria (protein
in the urine). About 10-30% of patients present with facial and
neck swelling. Approximately 2/3 of patients present with sore
throat, usually accompanied by objective inflammatory or exudative
(oozing) pharyngitis. Some patients experience adult respiratory
distress syndrome. Skin rashes and jaundice are rare. Some patients
experience bleeding from the gums. In addition, capillary lesions
cause hemorrhaging in the stomach, small intestine, kidneys, lungs,
and brain. Less than 1/3 of patients present with bleeding;
however, bleeding is a predictor of a significantly higher risk of
death. In severe cases of Lassa fever, shock and vascular collapse
occur, followed by death. Research suggests that the shock results
from platelet and endothelial dysfunction, which cause hemorrhage
and allow fluid to leak into the intravascular system. Patients who
will survive begin to defervesce 2-3 weeks after onset of the
disease. In contrast, patients who are at the greatest risk of
dying usually develop shock, clouded mental status, agitation,
rales, pleural effusion, and sometimes grand mal seizures. The four
symptoms associated with a 2.5-fold or higher risk of mortality
are: vomiting, sore throat, tachypnea (rapid breathing), or
bleeding. During convalescence, although the virus may no longer be
found in the blood, pericarditis can occur, especially in males.
The following conditions may also occur during convalescence:
aseptic meningitis, encephalitis, global encephalopathy with
seizures, cerebellar ataxia (uncommon), and deafness (common).
Temporary or permanent deafness in one or both ears occurs in 29%
of Lassa fever patients. Experiments on guinea pigs have shown that
Lassa virus can manifest differently, with significantly varying
symptoms. It is suspected that subtle genetic changes in
tissue-specific variants of the disease create the differences in
disease manifestation.
Click here to go at the top
7
-
29-05-2015
Diagnosis: Lassa virus can be diagnosed in three ways: 1.
Isolating the virus from blood, urine, or throat washings. 2.
Demonstrating the presence of immunoglobuline M (IgM)
antibody to Lassa virus. 3. Showing a fourfold rise in titer of
IgG antibody between
acute- and convalescent-phase serum. The virus can be isolated
from the blood or serum during the febrile phase of the disease, up
to 2 weeks postonset. Antibody can be detected by CF, IFA, or
ELISA. In severe cases, patients can die before the appearance of
antibodies. Other laboratory results:
Leukocyte count can be low, normal, or moderately elevated.
Platelet counts are usually normal, but might be slightly low. AST
(SGOT) and ALT (SGPT) are usually elevated (10x
normal). Chest x-rays are usually normal, but may show
pleural
effusions or basilar pneumonitis. Albuminaturia (excessive
amounts of albumin proteins in the
urine) is common. ECGs are usually abnormal.
Initial possible diagnoses of the Lassa-infected patient may
include malaria, shigellosis, and typhoid. Mortality Rates:
Prognosis for Lassa patients has a direct correlation to levels of
viremia. However, prognosis does not correlate with the patient's
development of IgM or IgG antibodies. The antibodies do not seem to
neutralize the Lassa virus. The mortality rates for Lassa virus are
typically estimated at 15% to 20%. Some studies estimate mortality
as high as 45%. One survey of Lassa infection vs. mortality rates
indicates that less than 1% of all Lassa-virus infections in West
Africa will eventually result in fatal disease. The mortality rates
for Lassa appear to be much higher in people of non-African stock.
Lassa virus also causes high fetal mortality and high mortality in
pregnant women. The mortality rate is 92% for fetuses in early
Click here to go at the top
8
-
29-05-2015
pregnancy, 75% for fetuses in the third trimester, and 100% in
the neonatal period for full-term babies. High concentrations of
the virus have been found in both fetal tissue and in the placenta.
It is suspected that maternal T cells cannot attack the
concentrations of virus in the placenta because placental cells
cannot express class I or class II MHC antigens. The mortality rate
for gravid women is 7% in the first two trimesters, 30% in the last
trimester, and 50% for pregnant women who delivered within 1 month.
In contrast, the general mortality rate for nonpregnant women only
is 13%. Treatment: For adults, ribavirin: 2-gm loading dose,
followed by 1 gm every 6 hours for 4 days; followed by 0.5 gm every
8 hours for 6 days. There is no treatment for the deafness (which
resembles idiopathic nerve disease) associated with Lassa fever.
Antibiotics may also be administered to patients to ward off or
treat secondary and/or opportunistic bacterial infections. Severely
ill patients may receive treatment before the diganosis is
confirmed. Currently, there is no effective prophylactic treatment
for Lassa fever. However, some sources recommend prophylactic doses
of Ribavirin for people coming in high-risk contact with viremic
patients. Outbreaks and History of Infection: Lassa fever was first
recognized in 1969 in Lassa, Nigeria. Subsequent outbreaks occurred
in Nigeria, Liberia, and Sierra Leone. In some parts of Sierra
Leone and Liberia, 10% to 16% of all patients admitted to hospitals
have Lassa fever. Some Lassa fever cases have been "imported" into
the U.S. and U.K. through viremic travelers who acquired the
disease elsewhere. A few notes on outbreaks: - 1969, northern
Nigeria - first recognized outbreak of the disease. - 1970 to
present, Liberia. Most cases were hospital workers who acquired the
disease in the hospital from the index patient. - 1970 to present,
Sierra Leone. It is estimated that 6% of all residents in the
initial endemic area have antibodies to Lassa Fever,
Click here to go at the top
9
-
29-05-2015
even though only 0.2% were recognized as clinically ill. -
Estimated 100,000-300,000 infections per year in West Africa. About
2/3 of all reported cases are women, but this might be a result of
exposure, rather than a tendency toward greater susceptibility in
women to the disease. Vaccine: No vaccine is currently available.
However, the most promising approach to developing a vaccine
appears to be via vaccinia-vectored Lassa genes. These have been
protective in both guinea pigs and nonhuman primates.
Jeenatara Begum Assistant Professor
GNIPST
DISEASE RELATED BREAKING NEWS Lassa Fever United States of
America: (28th
May, 2015) On 25 May, PAHO/WHO was informed that the United
States Center for Disease Control and prevention (CDC) and the New
Jersey Department of Health had confirmed a fatal case of Lassa
fever. The case was diagnosed on 25 May in a person returning to
the U.S. from Liberia. Read more
UPCOMING EVENTS 61st IPSF World Congress sponsored by Indian
Pharmaceutical
Association (IPA) at Marriott Hotel, Hyderabad, India is going
to on 30th July to 9th August, 2015.
Click here to go at the top
10
-
29-05-2015
DRUGS UPDATES FDA Approves Xifaxan (rifaximin) for the
Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) :
(27th May, 2015) Valeant Pharmaceuticals International, Inc. (NYSE:
VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix
Pharmaceuticals, Inc., has received approval from the U.S. Food and
Drug Administration (FDA) for Xifaxan 550 mg for the treatment of
IBS-D in adults. The FDA approval of Xifaxan 550 mg is based on
data from three phase 3 studies, TARGET 1, TARGET 2 and TARGET 3.
Xifaxan 550 mg was studied in over 3,000 patients and demonstrated
the efficacy and safety of repeat treatment following completion of
a two-week course of treatment. A full course of Xifaxan 550 mg for
IBS-D is available in a convenient 2 week pack of 42 pills. Read
more
CAMPUS NEWSFAREWELL PROGRAMME:
On 15th May 2015 GNIPST clebrated the farewell programme Sesh
Chithi for the final year students of M.Pharm, M.Sc, B.Pharm, B.Sc
and BHM.
JIS SAMMAN 2015 On 11th May, 2015 GNIPST attended the JIS SAMMAN
2015.
JIS SAMMAN Awards: Best College (Non Engineering):
GNIPST Best Principal:
Dr (Prof.) Avijit Sengupta Best HOD:
Mr. Jaydip Ray Best Faculty:
Mr. Debabrata Ghoshdastidar (Pharmacy)
Click here to go at the top
11
-
29-05-2015
Dr. Swati Chakraborty (Life Sciences) Best faculty since
inception:
Mr. Jaydip Ray Best Office Staff:
Ms. Jaya Banerjee Best technical Assistant:
Mr. Somnath Majhi College Blue:
Avik Paul Highest DGPA of 2014:
B.Pharm:Purbali Chakraborty (4th year) Diksha Kumari (3rd year)
Aishika Dutta (2nd year) Sampita Paul (1st year) M.Pharm: Aritra
Mukherjee (Pharmaceutical Chemistry) Mounomukhar Bhattacharya
(Pharmacology) B.Sc (Biotechnology): Papiya Saha (3rd year)
Shomasree Das (2nd year) Ayanita Basak (1st year) B.Sc
(Microbiology): Bonhisikha Chatterjee (3rd year) Riaz Hossain (2nd
year) Soumi Chowdhury (1st year) BHM: Bishal Roy (3rd year)
Shreyabhanja Chowdhury (2nd year) Recitation:
Udita Majumder Debate:
Srijita Roy Poushali Ganguly
Click here to go at the top
12
-
29-05-2015
Band: Syantan Ghoswami Anurag Ghosh Atanu Mondal Arka Khamaru
Ritobroto Paul Abhirup Dasgupta
Fashion: Md. Nadeem Shah Koustav Sarkar Shaksar Saha Avirup
Dasgupta Ranit Kundu Namrata Ganguly Shreyasee Mitra Chandrika Saha
Debopriya Chatterjee Riya Taran
Innovative Modeling: Ankit Chowdhury Kartik Koley Mudasar Manna
Dipan Chaterjee Abhishek Singh Kaustav Pal Manojit Dutta SPIRIT JIS
2015
On 03th to 05th April, 2015 JIS organised SPIRIT JIS 2015. GPAT
2015 Result:
The following B.Pharm. final year students have qualified,
GPAT-2015. We congratulate them all. Diksha Kumari Rupanjay
Bhattacharya Avik Paul
Click here to go at the top
13
-
29-05-2015
Xtasy 2015: GNIPST is going to organize the Tech Fest Xtasy 2015
from 30th March, 2015 to 1st April, 2015.
FINISHING SCHOOL TRAINING PROGRAMME: The FINISHING SCHOOL
TRAINING PROGRAMME is going to organize by the Entrepreneurship
Development Cell and Training & Placement Cell, GNIPST in
collaboration with Indian Pharmacy Graduates Association (IPGA),
Bengal Branch from 21st February to 11th April, 2015 at GNIPST
Auditorium. On 21
st February, 2015 the Finishing School Training Programme of
GNIPST was inaugurated by Sri Soumen Mukhopadhyay, Deputy
Director, Drug Control Office, Goutam Kr. Sen, President, IPGA, Mr.
Subroto Saha, Asst. Directorate, Drug Control Office, Mr. Ranendra
Chakraborty, Sales Manager and Associate Director Dr. Reddys
Laboratory. On 28th February, 2015 Dr. D. Roy, Former Deputy Drug
Controller, Mr. Sujoy Chakraborty, divisional Therapy Manager,
Cipla and Mr. Vikranjit Biswas, Senior Manager, Learning &
Development, Cipla delivered their valuable lectures in the 2nd day
FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 14th March, 2015
Mr. Milindra Bhattacharya, Senior Manager, QA & QC, Emami Ltd.
and Mr. Joydev Bhoumik, Manager, Operation, Ranbaxy Laboratory
Limited delivered their valuable lectures in the 3rd day FINISHING
SCHOOL TRAINING PROGRAMME of GNIPST. On 21st March, 2015 Mr. Tridib
Neogi, Associate Vice-President (Quality Assurance), Albert David
Ltd. delivered his valuable lectures in the 4th FINISHING SCHOOL
TRAINING PROGRAMME of GNIPST. On 28th March, 2015 Dr. Gautam
Chaterjee, an Alumni of Jadavpur University and presently
associated with NIPER delivered his valuable lectures in the 5th
FINISHING SCHOOL TRAINING PROGRAMME of GNIPST.
Click here to go at the top
14
-
29-05-2015
On 11th April, 2015 the closing ceremony of the FINISHING SCHOOL
TRAINING PROGRAMME was held in GNIPST Auditorium. JOBS:
All the students of Final Year B. Pharm and M. Pharm are hereby
informed that an interview will be conducted on 23rd May, 2015 by
Standard Pharmaceuticals Ltd. GSK for post: Production, QA, QC. All
the students of Final Year B. Pharm and M. Pharm are hereby
informed that an interview will be conducted by GSK for sales and
marketing job. Details given below:
Date: 27.03.2015Time: 09:45 amVenue : GSK Consumer Healthcare
Limited, Unit No. 208,
2nd Floor, Ecospace Campus B (3 B), New Town, Rajarhat, 24 Pgs
(N). Kolkata-700156.
THYROCARE provisionally selected 15 students from JIS Group.
Amongst these, 3 students of B. Sc (H) Biotechnology and M. Sc
Biotechnology have been selected. Ipsita Mondal (M. Sc
Biotechnology)Debriti Paul (M. Sc Biotechnology)Debopriya
Chatterjee {B. Sc (H) Biotechnology}
The final year students of B.Pharm (31 students) and B.Sc (11
students) attended the pooled campus drive of Abbott India Ltd. on
10th March, 2015 at Jadavpur University. Among them 17 students
have gone through to the final round of this pooled campus drive
and short listed for final selection.
ACHIEVEMENT: Congratulations to Anurag Chanda, student of
B.Pharm final year
who have got the 1st prize in poster presentation event in
Prakriti 2015 at Department of Agricultural and Food engineering,
IIT, Kharagpur.
Click here to go at the top
15
-
29-05-2015
OTHERS: On 24th and 25th February, 2015 Swamiji of Gourio
Mathwasdelivered some motivational lectuers in GNIPST.
The students of GNIPST participated in the 4th Sardar
JodhSinghTrophy organised by NIT on 20th February, 2015. On 8th
February, 2015 Gnipst celebrated the ReunionprogrammeReminiscence
Reloaded 2015.
STUDENTS SECTION WHO CAN ANSWER FIRST????
Think outside the box is the tagline of whichcompany?
Answer of Previous Issues Questions: A) Human genome project
Identify
Answer of Previous Issues Image: Larry Page and Sergey Brin,
founder of GOOGLE
Send your thoughts/Quiz/Puzzles/games/write-ups or any other
contributions for Students Section& answers of this Section at
[email protected]
Click here to go at the top
16
-
29-05-2015
EDITORS NOTE
It is a great pleasure for me to publish the 4th issue of 45th
Volume of GNIPST BULLETIN. All the followers of GNIPST BULLETIN are
able to avail the bulletin through facebook account GNIPST bulletin
I am very much thankful to all the GNIPST members and readers who
are giving their valuable comments, encouragements and supports. I
am also thankful to Dr. Abhijit Sengupta, Director of GNIPST for
his valuable advice and encouragement. Special thanks to Dr.
Prerona Saha, Mr. Debabrata Ghosh Dastidar and Mr. Soumya
Bhattacharya for their kind co-operation and technical supports.
Thank you Mr. Soumya Bhattacharya for the questionnaires of the
student section. An important part of the improvement of the
bulletin is the contribution of the readers. You are invited to
send in your write ups, notes, critiques or any kind of
contribution for the forthcoming special and regular issue.
ARCHIVE The general body meeting of APTI, Bengal Branch has
been
conducted at GNIPST on 15th June, 2012. The program started
witha nice presentation by Dr. Pulok Kr. Mukherjee, School of
NaturalProducts, JU on the skill to write a good manuscript
forpublication in impact journals. It was followed by nearly two
hourlong discussion among more than thirty participants on
differentaspects of pharmacy education. Five nonmember
participantsapplied for membership on that very day.
GNIPST is now approved by AICTE and affiliated to WBUT
forconducting the two years post graduate course (M.Pharm)in
PHARMACOLOGY. The approved number of seat is 18.
Click here to go at the top
17
-
29-05-2015
The number of seats in B.Pharm. has been increased from 60
to120.
AICTE has sanctioned a release of grant under ResearchPromotion
Scheme (RPS) during the financial year 2012-13toGNIPST as per the
details below:a. Beneficiary Institution: Guru Nanak Institution of
PharmaceuticalScience & Technology.
b. Principal Investigator: Dr. LopamudraDutta.c. Grant-in-aid
sanctioned:Rs. 16,25000/- only
d. Approved duration: 3 yearse. Title of the project: Screening
and identification of potential
medicinal plant of Purulia & Bankura districts of West
Bengal with respect to diseases such as diabetes, rheumatism,
Jaundice, hypertension and developing biotechnological tools for
enhancing bioactive molecules in these plants.
Activity Clubs of GNIPST: Name of Club Member Faculty SPORTS Mr.
Debabrata GhoshDastidar LITERARY AND PAINTING Ms. Jeenatara Begum
SCIENCE AND INNOVATIVE MODELLING
Mr. Samrat Bose
ECO Ms. Sumana Roy SOCIAL SERVICES Dr. Asis Bala PHOTOGRAPHY Ms.
Sanchari Bhattacharya CULTURAL Ms. Priyanka Ray DEBATE AND
EXTEMPORE Mr. Soumya Bhattacharya
Click here to go at the top
18
Smokers and those exposed to passive smoke require more
anesthetic and painkiller during operations: (29th May,2015)New
research shows that both smokers and those exposed to passive smoke
require more anesthetic and painkillers to reach the same level of
anesthesia as non-smokers. Before an operation, low blood pressure
rather than high is a risk factor for death: (29th May,2015)
New research suggests that, before an operation, low blood
pressure rather than high blood pressure is an independent risk
factor for death. Hypothermia occurs during surgery in around half
of patients: (29th May,2015)
A study shows that hypothermia occurs in around half of patients
undergoing surgery, despite national guidelines for its prevention.
Blood pressure medications can lead to increased risk of stroke:
(29th May,2015) Phase 2 trial identifies genetic dysfunction that
makes many types of cancer vulnerable to an immunotherapy: (29th
May,2015) Altered pain processing in patients with cognitive
impairment: (29th May,2015) Less-invasive method for kidney
diagnostics: (29th May,2015) Alzheimer's culprit causes memory loss
even before brain degeneration: (29th May,2015) Rewriting the book
on chemo-resistant cancers with a DNA library: (29th May,2015)
Biomarker analysis reveals several potential treatment targets in
subtype of anal cancer: (29th May,2015)
KNOWLEDGE BASED ARTICLELassa FeverDescription: An extremely
virulent, often fatal, Old-World, viral hemorrhagic illness. Lassa
fever, an arenavirus, is an enveloped, single-stranded, bisegmented
RNA virus. As with other arenaviruses, Lassa virus does not have a
conventional negative-... Lassa Fever United States of America:
(28th May, 2015)On 25 May, PAHO/WHO was informed that the United
States Center for Disease Control and prevention (CDC) and the New
Jersey Department of Health had confirmed a fatal case of Lassa
fever. The case was diagnosed on 25 May in a person returning to
the U....Read more FDA Approves Xifaxan (rifaximin) for the
Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) : (27th
May, 2015)Valeant Pharmaceuticals International, Inc. (NYSE: VRX)
(TSX: VRX) announced that its wholly owned subsidiary, Salix
Pharmaceuticals, Inc., has received approval from the U.S. Food and
Drug Administration (FDA) for Xifaxan 550 mg for the treatment of
...Read more CAMPUS NEWS STUDENTS SECTION